Holen Sie sich die Stockscreener-App
104.51
0.34%
-0.36
Schlusskurs vom Vortag:
$104.87
Offen:
$105.05
24-Stunden-Volumen:
401.03K
Relative Volume:
0.48
Marktkapitalisierung:
$4.84B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.78M
KGV:
-39.00
EPS:
-2.68
Netto-Cashflow:
$-53.91M
1W Leistung:
-2.10%
1M Leistung:
+0.29%
6M Leistung:
+99.56%
1J Leistung:
+728.13%
1-Tages-Spanne:
$103.16
$107.75
1-Wochen-Bereich:
$97.49
$110.40
52-Wochen-Spanne:
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
104.51 | 4.85B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Commit To Purchase Celcuity At $45, Earn 17.8% Using Options - Nasdaq
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Soleus Adds a Significant Number of Celcuity Shares - The Globe and Mail
Soleus Capital Increases Stake in Celcuity - Intellectia AI
Is Celcuity’s New Oncology Commercial Leader Appointment Reshaping the Investment Case for CELC? - simplywall.st
Soleus Adds a Significant Number of Celcuity Shares - The Motley Fool
Celcuity Adds Veteran Director to Strengthen Oncology Strategy - TipRanks
Celcuity Appoints Charles Romp to its Board of Directors - Yahoo Finance
Discipline and Rules-Based Execution in CELC Response - Stock Traders Daily
Can Celcuity Inc. ride the EV waveJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - mfd.ru
Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference - MarketBeat
CELC: Gedatolisib nears approval with strong efficacy, broad utility, and major commercial potential - TradingView
Candriam S.C.A. Increases Holdings in Celcuity, Inc. $CELC - MarketBeat
Inflation Data: Does Celcuity Inc align with a passive investing strategyJuly 2025 Pullbacks & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-02-08 07:23:47 - baoquankhu1.vn
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump - The Globe and Mail
Wall Street Recap: Is Celcuity Inc stock a smart retirement pickGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Profit Review: Can Celcuity Inc ride the EV wave2025 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Assessing Celcuity (CELC) Valuation After Recent Share Price Momentum And DCF Upside Estimate - Yahoo Finance
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst By Investing.com - Investing.com South Africa
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst - Investing.com Nigeria
Biotech Stocks To ResearchFebruary 4th - MarketBeat
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Wealth Enhancement Advisory Services LLC Sells 10,476 Shares of Celcuity, Inc. $CELC - MarketBeat
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances - Insider Monkey
Jobs Data: Whats the beta of Celcuity Inc stockTrade Entry Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Behavioral Patterns of CELC and Institutional Flows - Stock Traders Daily
Atle Fund Management AB Takes $1.84 Million Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity granted FDA priority review for breast cancer therapy - MSN
Celcuity prices $248.7M debt, stock offerings - MSN
Celcuity Inc. (CELC) Stock Analysis: Navigating High Potential in Biotechnology with a $5.19 Billion Market Cap - DirectorsTalk Interviews
Assessing Celcuity (CELC) Valuation After FDA Priority Review Milestone For Gedatolisib - Sahm
Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock - MarketBeat
Celcuity stock hits all-time high at 116.65 USD By Investing.com - Investing.com Australia
Celcuity (CELC) Is Up 11.3% After FDA Grants Priority Review To Gedatolisib NDAWhat's Changed - simplywall.st
Celcuity (NASDAQ:CELC) Reaches New 52-Week HighTime to Buy? - MarketBeat
Celcuity stock hits all-time high at 116.65 USD - Investing.com
Celcuity Inc. Earnings Call: Strong Progress Amid Challenges - MSN
Celcuity, Inc. (NASDAQ:CELC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celcuity Inc: A Die To Be Cast Before July 2026 (NASDAQ: CELC) - Seeking Alpha
Celcuity Inc. (CELC) Stock Analysis: Exploring the Biotechnology Innovator’s Growth Potential - DirectorsTalk Interviews
Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain - Yahoo Finance
(CELC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
FDA accepts Celcuity’s NDA for gedatolisib with priority review By Investing.com - Investing.com South Africa
Celcuity wins FDA review for breast cancer drug (CELC:NASDAQ) - Seeking Alpha
FDA Accepts Celcuity's NDA For Gedatolisib In HR+, HER2- Advanced Breast Cancer - Nasdaq
FDA accepts Celcuity’s NDA for gedatolisib with priority review - Investing.com
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - manilatimes.net
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):